Single Dose, Open-label, Randomized, Crossover Study in Subjects With Severe Hemophilia A Comparing Pharmacokinetic Parameters for BAY81-8973 and Advate

Trial Profile

Single Dose, Open-label, Randomized, Crossover Study in Subjects With Severe Hemophilia A Comparing Pharmacokinetic Parameters for BAY81-8973 and Advate

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Dec 2016

At a glance

  • Drugs Octocog alfa (Primary) ; Rurioctocog alfa
  • Indications Haemophilia A
  • Focus Pharmacokinetics
  • Sponsors Bayer
  • Most Recent Events

    • 22 Dec 2016 Results published in the Clinical Pharmacokinetics
    • 19 Jan 2016 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 16 Oct 2015 Planned End Date changed from 1 Nov 2015 to 1 Oct 2015 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top